TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phyllodes Tumor Partial Breast Radiation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic proof of phyllodes tumor of borderline or malignant grade, as first defined by Pietruszka and modified by Azzopardi and adopted by the World Health Organization (1,2,17):~  * Borderline malignant: 5-9 mitoses/10 HPF, pushing or infiltrating margins, 2+ (moderate) stromal cellularity and atypia.~ * Malignant: 10 or more mitoses / 10 HPF, predominantly infiltrating margins, usually 3+ (severe) stromal cellularity and atypia but occasionally 2+.~* The tumor has been excised with a breast-conserving resection and there is no tumor seen at any of the margins of the resection.~* No prior breast carcinoma or ductal carcinoma in situ in the ipsilateral breast. Patients with a local recurrence of a previously excised phyllodes tumor are eligible if the recurrence is in the area of the previous excision.~* No history of irradiation of the ipsilateral breast.~* No evidence of other areas worrisome for cancer on physical examination and mammography of the ipsilateral breast.~* Age \>18 years.~* Informed consent.~* Documentation that either:~  1. the patient's medical insurance company has certified that they will pay for the cost of radiation therapy treatments, or~ 2. a letter from the patient indicating that they explicitly understand the costs of radiation therapy and that the sponsor (Principal Investigator) of this study will not be held responsible for these costs.~Exclusion Criteria:~* Histologically positive margins.~* Breast carcinoma or ductal carcinoma in situ in the ipsilateral breast.~* A history of irradiation to the ipsilateral breast.~* Pregnancy. A urine pregnancy test will be performed on each fertile premenopausal female prior to entry into the study. Patients with childbearing potential must employ effective contraception during the radiation therapy.~* A radiation planning CT scan which demonstrates a target lumpectomy cavity that is not clearly delineated or a target lumpectomy cavity/whole breast reference volume \> 30%.~* Unacceptable radiation therapy quality assurance parameters, as defined in Section 5 of the protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Partial breast radiation after lumpectomy (Type: OTHER): Radiation per NSABP B-39/R0413 protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable of giving informed consent~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes~Exclusion Criteria:~1. Current or past diagnosis of endophthalmitis~2. Current diagnosis of uveitis~3. Current use of viscous lidocaine products for ocular anesthesia prior to IVT~4. Currently receiving intravitreal steroid injections~5. Concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test Drug (Type: EXPERIMENTAL): IRX-101 drops instilled prior to intravitreal injection
- Control (Type: ACTIVE_COMPARATOR): Povidone-Iodine/Betadine drops instilled prior to intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Zinc Sulfate for Human Papillomavirus (HPV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on Pap smear OR~* Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR~* Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)~Exclusion Criteria:~* Patients who proceed to excisional procedures (loop electrosurgical excision procedure or cold knife conization)~* Pregnant patients~* Breastfeeding patients~* Immunocompromised patients

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Zinc Sulfate 220mg twice daily for three months.
- Placebo (Type: PLACEBO_COMPARATOR): Gelatin Placebo tablet twice daily for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients ≥18 years old~* Undergoing non-emergent exploratory laparotomy with the Gynecologic Oncology service~* No clinical or laboratory evidence of end organ failure:~If available:~* Platelets \> 100 K/cumm~* Hemoglobin \> 8.0 g/dl~* Serum creatinine \<1.5 mg/dl~* Creatine clearance (CrCl) ≥30 based on the original Cockcroft-Gault formula adjusted for weight.~* INR \<1.3 reference range~* All other lab values obtained as part of general preoperative work-up must be ≤1.5x normal laboratory value.~Exclusion Criteria:~* Patients not giving consent to participate in the study~* Unable to complete self-report pain questionnaire~* Moderate to severe kidney or liver failure per lab criteria as outlined~* Inability to hold anticoagulant medications for a safe amount of time per current ASRA guidelines~* Contraindication to lumbar puncture or epidural placement, per acute pain management service such as known coagulopathy or history of clotting disorders, history of scoliosis or lumbar fusion, infection at site of entry, or current systemic infection~* Complete bowel obstruction~* Contraindication to intravenous lidocaine~* No known pregnancy and not lactating.~* Currently septic~* Patient currently taking more than 30 MME a day preoperatively (for \>30 days)~* BMI \>50kg/m2~* Intolerance/contraindication or allergy to receiving non-steroidal anti-inflammatory drugs or acetaminophen or any other medications in the pre-operative order set

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA) (Type: ACTIVE_COMPARATOR): * Standard of care at Washington University School of Medicine/Barnes-Jewish Hospital~* Day of surgery: preoperative tylenol, gabapentin, celebrex, and epidural dosing per standard protocol.~* Intraoperative: dexamethasone and epidural bupivacaine~* Day of surgery postoperative: hydromorphone PCA, toradol, ibuprofen, tylenol, epidural bupivacaine~* Postoperative: hydromorphone PCA, ibuprofen, oxycodone
- Intrathecal morphine with intraoperative lidocaine infusion (Type: EXPERIMENTAL): * Day or surgery: tylenol, gabapentin, celebrex, and preoperative intrathecal morphine one time injection (150mcg)~* Intraoperative: dexamethasone and lidocaine infusion 1 mg/kg ideal body weight~* Day of surgery postoperative: toradol, ibuprofen, tylenol~* Postoperative: ibuprofen, oxycodone, and hydromorphone prn

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or over~* Written informed consent~* Willingness to attend follow-up visits~* Central serous chorioretinopathy affecting visual acuity~* Macular edema from branch retinal vein occlusion~* Macular edema from diabetic microangiopathy~* Age-related macular degeneration with confluent soft drusen~* Age-related macular degeneration with geographic atrophy~Exclusion Criteria~* Macular ischemia~* Retinal hemorrhage impeding retinal laser treatment~* Subretinal neovascular membrane~* Vitreous hemorrhage~* Allergy to fluorescein~* Participation in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients receive selective retinal pigment epithelium laser treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: LOTCOL Study: Local Treatment of Colo-rectal Liver Met

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified adenocarcinoma of colon or rectum~* Ambulatory with an ECOG performance status 0-2~* At least 18 years of age~* Non-resectable liver metastases~* Progressive disease on or within 4 months after 1.line chemotherapy for KRAS mutant or after 2.line chemotherapy in KRAS wild type patients~* 1-4 liver metastases with largest diameter of up to 6 cm on CT-scan~* Up to 20 lesions in liver with no more than 4 lesions larger than 4 cm~* The patients will start 2./3. line chemotherapy (KRAS mutant/KRAS wt)~* Laboratory values as the following:~  * ANC ³ 1.5 x 109/L~ * Platelets ³ 100 x 109/L~ * Hb ³ 9g/dL~ * Creatinine £ 2x upper limit of normal~ * Bilirubin \< 2.0x the upper limit of normal~ * ASAT and ALAT £ 5x the upper limit of normal~ * Albumin levels \> 30 g/L~ * INR\<1.3~* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations~Exclusion Criteria:~* Previous treatment with 2. or 3. line chemotherapy (KRAS mutant/KRAS wt)~* History of prior metastatic disease the last 3 years~* History of CNS or bone metastases~* Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia~* Largest liver mets \>6 cm, more than 4 liver lesions \>4 cm~* Pulmonary mets\>3 cm~* Lymph node mets \>2.5 cm~* Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start of treatment~* Any reason why, in the opinion of the investigator, the patient should not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cheomotherapy and local treatment (Type: EXPERIMENTAL): Standard chemotherapy + local treatment
- Cheomotherapy (Type: PLACEBO_COMPARATOR): Standard chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: [124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females age \>18 years~2. Ability to provide informed consent~3. A plain anterior-posterior (AP) and frog leg lateral X-ray of the hip or knee within 6 weeks of enrollment~4. Need for operative intervention in the opinion of the surgeon to correct the pain in the prosthetic joint~5. Prosthetic joint implant that has been in site for more than 3 months prior to enrolment~6. Having adequate general health to be expected to tolerate surgery adn to survive for 6 months from the time of informed consent~7. Women must be either postmenopausal or surgically sterile~8. Ability to return for all study assessments~9. Clinically euthyroid, or on stable thyroid replacement therapy~Exclusion Criteria:~1. Subjects who are unable to comply with study requirements~2. Indication, in the opinion of the principal investigator, for urgent surgery that would preclude the time needed for PET-CT scanning~3. History of an inherited mitochondrial disorder (e.g., Leber's hereditary neuropathy; neuropathy; ataxia, retinitis pigmentosa and ptosis \[NARP\]; myoneurogenic gastrointestinal encephalopathy \[MNGIE\]; myocolonic epilepsy with ragged red fibers \[MERFF\]; and mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like syndrome \[MELAS\])~4. Alanine aminotransferase (ALT) \>5x the upper limit of normal (ULN) OR aspartate aminotransferase (AST) \>5X ULN~5. Creatinine clearance \<30 mL/min~6. Body mass that exceeds the rating of the CT table~7. Hypersensitivity to iodine~8. Any condition that would put the subject at reasonable risk in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [124I]FIAU (Type: EXPERIMENTAL): Single dose study of \[124I\]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Adaptated Physical Activity During Chemotherapy: Evaluation of the Psychological, Physiological and Biological Impact

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 18 years or more,~* Performance status (WHO) ≤ 2~* Ability to participate in the IPCAPA program and medical certification of no contraindications to exercise~* Availability and willingness to participate in the IPCAPA study for the duration of the protocol~* Affiliated to a social security system~* Signed informed consent.~Exclusion Criteria:~* Pregnant or breastfeeding woman.~* Woman with childbirth ability without effective contraception.~* Patient in emergency situations, adult subject to a measure of legal protection (major trusteeship, guardianship or ward of court), or unable to consent.~* Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.~* Inability to practice physical activity.~* Planned surgery within 24 weeks of inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate adaptated physical activity (Group A) (Type: OTHER): Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4).
- Without immediate adaptated physical activity (Group B) (Type: OTHER): Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy Associating CPAP and Mandibular Advancement Device in OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Arterial Hypertension (Clinical Blood Pressure \> 140/90 mmHg or patient under medication with nocturnal hypertension seen in the Ambulatory Blood Pressure Measurement)~* Severe obstructive sleep apnea syndrome, treated by CPAP for more than 6 months and less than 5 years, with a compliance \<4h/night~* No contraindication to a treatment by Mandibular Advancement Device~* Ability to understand study procedures and signed informed consent~* Covered by French social security system or equivalent~Exclusion Criteria:~* Central Obstructive Apnea (\>20% Central Apneas/Hypopneas)~* Pregnant or breastfeeding womens~* Prisoners or persons who require protection by the law~* Persons within the exclusion period of another study~* Contraindication to a mandibular advancement device (oral-dental pathology, pathology of the temporo-mandibular articulation, poor periodontal status)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CPAP only (Type: ACTIVE_COMPARATOR): Obstructive sleep apnea patients with CPAP treatment only
- Mandibular Advancement Device only (Type: ACTIVE_COMPARATOR): Obstructive sleep apnea patients with Mandibular Advancement Device only
- CPAP + Mandibular Advancement Device (Type: EXPERIMENTAL): Obstructive sleep apnea patients with combined CPAP and Mandibular Advancement Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* subjects with neurogenic bladders secondary to spinal cord injury~Exclusion Criteria:~* prior augmentation procedures or urinary diversion~* recent urologic or intraperitoneal surgery or device implantation~* recent history of spinal cord injury of less than a year~* recent neurologic surgery~* requirement for concomitant urological surgical procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated IRB/Approved Informed Consent~* Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after more than one prior systemic therapy for advanced / metastatic disease~* Presence of measurable disease~* Age \>=18 years old~* ECOG performance status 0-1~* Negative pregnancy test (if female in reproductive years)~* Use of effective contraceptive methods if men and women of child producing potential~* Adequate liver function Total Serum Bilirubin \<=1.5 x upper limit of normal (ULN) Transaminases (AST/ALT) \<=2.5ULN (if liver metastases are present, then \<=5ULN is allowed) ALP \<=2.5ULN (if liver and/or bone metastases are present, then \<=5ULN is allowed)~* Adequate renal function Serum Creatinine \<=ULN or Creatinine Clearance calculated by Cockcroft and Gault's formula \> 60 mL/min~* Adequate hematologic status ANC \>=1,500cells/mm3 Platelet Count \>= 100,000cells/mm3 Hemoglobin \>=9.0g/dL~* Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)~* Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade \<=1~Exclusion Criteria:~* Any of the following in the past 6 months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis~* Grade \>1 retinopathy~* Known brain metastases~* Known active infections~* Pregnant or breast feeding women~* Diabetes mellitus uncontrolled~* Gastrointestinal disease that would impact on drug absorption~* Patients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baseline~* Patients with previous history or current presence of neurological disorders (with the exception of myasthenia gravis), including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes.~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that make the patient inappropriate for entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Milciclib (Type: EXPERIMENTAL): Milciclib Maleate capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.~Exclusion Criteria:~Not specified.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy